Does Medicare Cover Zepbound in 2026?

Quick Answer: It Depends on Indication and Plan Type

It depends on the indication and your plan type. Zepbound for obesity is excluded from standard Part D by statute, but the 2026 CMS GLP-1 Bridge Program covers it at $50 per month for eligible Medicare Part D enrollees starting July 1, 2026. Zepbound for obstructive sleep apnea may be covered under standard Part D because OSA is not a statutorily excluded condition. Medicare Advantage plans vary widely: some cover Zepbound as a supplemental benefit for either indication.

Why Original Medicare Part D Does Not Cover Zepbound for Obesity

Original Medicare Part D is governed by Social Security Act Section 1927(d)(2)(A), which specifically prohibits Part D plans from covering agents when used for anorexia, weight loss, or weight gain. This statutory exclusion predates GLP-1 medications and applies equally to Zepbound (tirzepatide), Ozempic and Wegovy (semaglutide), and any other drug prescribed primarily for obesity or weight management. Congress would need to pass new legislation to change this exclusion; CMS cannot waive it on its own.

The TREAT Act and similar legislative proposals to remove the weight-loss drug exclusion from Part D were introduced in prior sessions of Congress but had not been enacted as of the 2026 plan year. Beneficiaries and advocates continue to push for legislative repeal. Until Congress acts, the statutory bar remains in place for standard Part D plans.

The 2026 CMS GLP-1 Bridge Program: How It Works

CMS launched the GLP-1 Bridge Program as part of the 2026 Medicare Advantage and Part D Final Rule, effective July 1, 2026. Under this program, Medicare Part D beneficiaries with obesity meeting specific BMI and comorbidity criteria can access tirzepatide (Zepbound) at a $50 per month copay through participating pharmacies. Qualifying criteria: BMI 35 or higher (any comorbidity); BMI 30 or higher with heart failure with preserved ejection fraction (HFpEF), uncontrolled hypertension, or CKD stage 3a or higher; or BMI 27 or higher with prediabetes, prior heart attack, stroke, or peripheral artery disease. The program is designed as a bridge while Congress weighs legislative action on the broader Part D exclusion.

One critical detail about the 2026 GLP-1 Bridge Program: the $50 copay does not count toward the $2,100 Part D out-of-pocket cap. That cap, set by the Inflation Reduction Act of 2022, applies to standard Part D cost-sharing. Because tirzepatide for obesity is excluded from the standard Part D benefit, the Bridge Program funds its coverage outside that framework. Beneficiaries pay $50 per month regardless of how much they have already spent on other Part D drugs. For beneficiaries relying on the OOP cap to manage high drug costs, this is an important planning consideration.

Zepbound for Obstructive Sleep Apnea: A Different Coverage Path

The FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity in November 2024, marking it as the first drug specifically approved to treat OSA. This approval matters for Medicare coverage because OSA is not on the Social Security Act's list of excluded indications. When a prescriber writes for Zepbound specifically for OSA (using the correct ICD-10 diagnosis code G47.33) rather than for weight loss, standard Part D formulary rules apply.

Whether a specific Part D plan covers Zepbound for OSA depends on that plan's formulary. As of the 2026 plan year, many Part D plans had not yet added tirzepatide for the OSA indication, and those that did typically placed it on a specialty tier with a 2026 coinsurance of 25% to 33%. At list prices of $550 to $1,000 per month, that translates to $138 to $330 per month before the plan's deductible and before the $2,100 OOP cap provides relief. Medicare beneficiaries should use the Medicare Plan Finder at medicare.gov to check whether their specific plan covers Zepbound for OSA in 2026.

Medicare Advantage Plans and Zepbound in 2026

Medicare Advantage plans (Part C) operate under different rules than Original Medicare. MA plans can offer supplemental benefits that cover drugs excluded from standard Part D, including weight-loss medications. Some MA plans added GLP-1 coverage as a 2026 supplemental benefit, though the landscape varies significantly across the more than 3,800 Medicare Advantage plans offered nationwide.

Medicare Advantage enrollees should request their plan's 2026 Evidence of Coverage (EOC) document and look for tirzepatide or Zepbound specifically in the drug formulary or supplemental benefit section. Plans that do cover Zepbound for obesity under a supplemental benefit set their own cost-sharing rules, which may be structured differently from the $50 GLP-1 Bridge copay. During the Annual Enrollment Period (October 15 through December 7, 2026 for coverage beginning January 1, 2027), beneficiaries can compare MA plans by GLP-1 coverage using the Medicare Plan Finder.

Cost Without Coverage: Self-Pay and Manufacturer Options in 2026

Medicare beneficiaries who do not qualify for the GLP-1 Bridge Program and whose plan does not cover Zepbound for OSA face full out-of-pocket cost. Zepbound's 2026 list price from Eli Lilly runs approximately $1,060 per month for the auto-injector pen doses (2.5 mg through 15 mg). Eli Lilly's LillyDirect program offers Zepbound vials at $299 to $449 per month without insurance for cash-pay patients, which is a meaningful alternative for those who can manage the self-injection process.

Eli Lilly's Zepbound Savings Card is available for commercially insured patients but is generally not available to Medicare beneficiaries (federal anti-kickback statute bars manufacturer coupons for federally insured patients). The LillyDirect self-pay vial program is distinct from the savings card and is available to Medicare patients paying fully out of pocket without applying any insurance benefit. Beneficiaries should confirm current program terms directly with Eli Lilly at lillydirect.com before enrolling.

Extra Help and Low-Income Subsidy: How It Interacts with Zepbound

Medicare's Extra Help program (also called the Low-Income Subsidy, or LIS) reduces Part D drug costs for beneficiaries with limited income and resources. In 2026, full Extra Help beneficiaries pay a $12.65 copay for covered brand-name drugs. Extra Help eligibility in 2026 requires income at or below 150% of the federal poverty level, which is $23,940 for an individual or $32,460 for a household of two.

Extra Help reduces cost-sharing only where the plan's formulary already covers the drug. For Zepbound, this means Extra Help applies: (1) under the GLP-1 Bridge Program for obesity at the $50 per month copay rate (the Bridge Program sets its own copay structure, so whether Extra Help further reduces this to $12.65 depends on final CMS implementation guidance); and (2) under standard Part D coverage for OSA, where a plan covers Zepbound on its formulary and Extra Help applies its standard brand copay of $12.65 in 2026.

Alternatives If Medicare Does Not Cover Zepbound

For Medicare beneficiaries who cannot access Zepbound through the Bridge Program or their plan's formulary, several alternatives exist.

• LillyDirect self-pay vials: Zepbound vials are available at $299 to $449 per month in 2026 through LillyDirect without insurance, for patients who self-inject. Pen devices cost significantly more out of pocket.
• Semaglutide (Wegovy): Also a GLP-1 receptor agonist FDA-approved for obesity. Excluded from standard Part D for the same statutory reason. Also available through the 2026 GLP-1 Bridge Program or via Medicare Advantage supplemental benefits depending on plan.
• Switch to a Medicare Advantage plan with GLP-1 coverage: During the Annual Enrollment Period (October 15 through December 7, 2026 for 2027 coverage), beneficiaries can switch to an MA plan that covers Zepbound as a supplemental benefit. Use the Medicare Plan Finder at medicare.gov to filter by drug coverage.
• CPAP therapy for OSA: If the goal is treating obstructive sleep apnea, Original Medicare Part B covers CPAP devices and supplies as durable medical equipment when prescribed by a physician and supported by a qualifying sleep study. CPAP is typically more affordable than Zepbound for OSA in the Medicare context.
• Patient Assistance Programs: Eli Lilly operates a patient assistance program (LillyAnswers) for low-income patients. Medicare beneficiaries with very low income who do not qualify for Extra Help may be eligible. Call 1-800-545-5979 or visit lilly.com for current 2026 program terms.

How to Find Out If Your Plan Covers Zepbound in 2026

Medicare Plan Finder at medicare.gov is the fastest way to check whether a specific Part D or Medicare Advantage plan covers Zepbound in 2026. Enter the drug name (tirzepatide or Zepbound), your zip code, and the indication (obesity or OSA) to see which plans cover it and at what cost. The tool shows formulary tier, cost-sharing at each phase (deductible, initial, and catastrophic), and whether prior authorization is required.

• Step 1: Go to medicare.gov/plan-compare and select Find a Drug Plan or Medicare Advantage Plan.
• Step 2: Enter your Medicare number or choose to browse anonymously. Enter your zip code.
• Step 3: Add tirzepatide (Zepbound) to your drug list. Specify the dose and indication.
• Step 4: Review the plans sorted by estimated annual drug cost. Look for plans covering Zepbound under the OSA ICD-10 code or the GLP-1 Bridge Program.
• Step 5: Contact the plan directly to confirm GLP-1 Bridge Program participation and any prior authorization requirements before enrolling.

Does Original Medicare Part D cover Zepbound for weight loss in 2026?

Standard Part D does not cover Zepbound for weight loss due to a statutory exclusion in Social Security Act Section 1927(d)(2)(A). However, starting July 1, 2026, the CMS GLP-1 Bridge Program covers tirzepatide (Zepbound) for obesity at a $50 per month copay for eligible Part D enrollees. That $50 copay does not count toward the 2026 Part D out-of-pocket cap of $2,100.

Does Medicare cover Zepbound for sleep apnea?

Possibly, through standard Part D. The FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in November 2024. Because OSA is not a statutorily excluded indication, Part D plans may cover tirzepatide when prescribed for OSA with the ICD-10 code G47.33. Coverage is plan-specific: use the Medicare Plan Finder at medicare.gov to check your plan's 2026 formulary.

What is the GLP-1 Bridge Program and how do I enroll?

The CMS GLP-1 Bridge Program is a Medicare initiative effective July 1, 2026 that covers tirzepatide (Zepbound) for obesity at a $50 per month copay for Part D enrollees. Enrollment flows through your existing Part D plan. Ask your plan whether it participates and whether your prescriber needs to submit specific documentation of BMI and weight-related conditions. The $50 copay does not apply toward the $2,100 Part D OOP cap for 2026.

Does Medicare Advantage cover Zepbound?

Some Medicare Advantage plans added GLP-1 coverage as a 2026 supplemental benefit, but coverage varies widely across the 3,800-plus MA plans. Review your plan's 2026 Evidence of Coverage document or call member services. During the Annual Enrollment Period (October 15 through December 7, 2026), you can switch to an MA plan that covers Zepbound. Use the Medicare Plan Finder at medicare.gov to compare plans by drug coverage.

How much does Zepbound cost without Medicare coverage in 2026?

Zepbound auto-injector pens list at approximately $1,060 per month in 2026. Eli Lilly's LillyDirect program offers Zepbound vials at $299 to $449 per month for cash-pay patients without insurance. Manufacturer savings cards are generally not available to Medicare beneficiaries under federal anti-kickback rules. The LillyDirect self-pay vial program is an exception and is available to Medicare patients paying fully out of pocket.

Can Extra Help (Low Income Subsidy) reduce my Zepbound cost?

Yes, if your plan covers Zepbound. Extra Help in 2026 limits brand-name drug copays to $12.65 per month for full-benefit recipients. Eligibility requires income at or below 150% of the federal poverty level ($23,940 for an individual in 2026). Extra Help applies only where the plan's formulary already covers the drug, so it interacts with OSA-indication coverage or GLP-1 Bridge Program access, not with excluded Part D weight-loss coverage.

What is the difference between Zepbound and Mounjaro?

Both are tirzepatide made by Eli Lilly, but FDA-approved for different conditions. Mounjaro is approved for type 2 diabetes management. Zepbound is approved for chronic weight management and obstructive sleep apnea. Medicare Part D covers Mounjaro for diabetes under standard formulary rules (it is not excluded). Zepbound for obesity is excluded from standard Part D. For OSA, Zepbound may be covered per plan formulary. The distinction in FDA indication and ICD-10 code determines which coverage path applies.

What alternatives exist if Medicare will not cover Zepbound?

Five main alternatives in 2026: (1) LillyDirect self-pay vials at $299 to $449 per month, available to Medicare patients paying out of pocket; (2) Wegovy (semaglutide), also covered under the GLP-1 Bridge Program for obesity; (3) Switch to a Medicare Advantage plan with GLP-1 supplemental coverage during open enrollment; (4) CPAP therapy for OSA, covered under Medicare Part B as durable medical equipment; (5) Eli Lilly's LillyAnswers patient assistance program for qualifying low-income Medicare beneficiaries.